GlobeNewswire by notified

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group

Share

Funds will be used to complete phase 3 clinical development of eneboparatide (AZP-3601) for hypoparathyroidism, and advance AZP-3813 into the clinic for acromegaly

LYON, France and CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the closing of a €130 million (approx. $138M) Series C equity financing. The financing was led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG). Cédric Moreau, partner at Sofinnova Partners and Toby Sykes, managing director at ICG, will join Amolyt’s Board of Directors. In addition, new investors, funds managed by Tekla Capital Investment LLC, and CTI Life Sciences along with existing investors Andera Partners, Novo Holdings (Novo Ventures), Kurma Partners, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital, participated in the round.

Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.  

“We are very pleased to complete this large Series C financing, which will enable us to build on our momentum with eneboparatide and accelerate the growth of Amolyt Pharma and its pipeline globally,” stated Thierry Abribat, Ph.D., founder, and chief executive officer of Amolyt Pharma. “We are thankful to Sofinnova Partners and ICG for co-leading this financing round, and to all our new and existing investors for their confidence in our team and for their support of our strategy to build a global and sustainable rare disease company. This investment will allow us to continue working tirelessly on bringing novel, life-changing treatments to patients with rare endocrine and related diseases.”

Cédric Moreau, partner of Sofinnova Crossover I fund, stated: “Amolyt is a strategic fit for our fund where we invest in companies that develop innovative medicines to address high unmet medical needs. With its unique mechanism of action, Amolyt’s lead compound eneboparatide has the potential to significantly improve the lives of patients with hypoparathyroidism. With this Series C financing, we believe that Amolyt's seasoned and passionate management team will be well-positioned to further evaluate eneboparatide’s differentiated profile through late-stage development and continue to grow its internal pipeline. We are committed to helping Amolyt become a leader in the rare endocrine space.”

The Series C financing follows several recent positive pipeline development and corporate announcements:

  • In September 2022, Amolyt presented positive efficacy and safety data from the first cohort of its Phase 2a study of eneboparatide at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR).
  • In October 2022, the company announced positive results from the second patient cohort in its Phase 2a clinical proof of concept trial of eneboparatide. Consistent with the findings from the first cohort of the study, eneboparatide was well-tolerated. Daily administration of eneboparatide over 3 months enabled 93% of patients to discontinue standard of care therapy (oral calcium and vitamin D supplementation) while mean serum calcium was maintained within the target range. 24-hour urinary excretion of calcium was rapidly normalized in all but one patient, including those with hypercalciuria at baseline. Bone turnover biomarkers, P1NP and CTX, increased after two weeks of treatment and remained within their mid-normal range through the end of the study, consistent with a balanced increase in bone turnover.

About Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.

Media inquiries:
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
+1 646.876.5196

Investor inquiries:
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
+1 617.430.7577

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sword Group: NOTICE OF CONVOCATION TO THE SHAREHOLDERS FOR THE ANNUAL ORDINARY GENERAL MEETING OF THE COMPANY28.3.2024 18:00:00 CET | Press release

General Meeting on April 29, 2024, at 11:00 am at the registered office to deliberate on the following agenda: Under the authority of the General Meeting acting under the quorum and majority conditions of an Ordinary General Meeting: - Reading of the management report of the Board of Directors including the group management report and feedback on the conclusion of agreements referred to in article L.441-7 of the amended law of August 10, 1915, for the financial year ended December 31, 2023; - Reading of the report of the approved statutory auditor on the 2023 annual accounts, the group's consolidated financial statements, and on the execution of its mission; - Approval of the statutory accounts as of December 31, 2023; - Approval of the consolidated accounts as of December 31, 2023; - Allocation of the statutory exercise results as of December 31, 2023; - Discharge to the directors for their management for the financial year 2023; - Renewal of Mr. Jacques Mottard's director term; - Ren

Sword Group: H2 2023 Report of the Liquidity Agreement28.3.2024 18:00:00 CET | Press release

Sword Group - H2 Report of the Liquidity Agreement contracted with ODDO BHF from 01/07/2023 au 31/12/2023 Under the liquidity contract awarded by Sword Group to ODDO BHF, as of 31/12/2023, the following resources appeared on the account of liquidity: 8,959 shares €359,040 - Number of transactions executed during the semester at purchase: 1,116 - Number of transactions executed during the semester on sale: 1,080 - Volume exchanged over the semester upon purchase: 34,943 shares for an amount of €1,319,183 - Volume exchanged over the semester for sale: 38,733 shares for an amount of €1,455,889 As a reminder, during the last balance sheet of 30/06/2023, the following resources appeared in the liquidity account: 12,749 shares €353,334 The implementation of the liquidity contract is carried out in accordance with AMF Decision No. 2018-01 dated July 2, 2018, establishing liquidity contracts on equity securities as accepted market practice. About Sword Group Sword has 3,000+ IT/Digital & Softw

Sword Group: Availability of the 2023 Financial Report28.3.2024 18:00:00 CET | Press release

Sword Group - Availability of the 2023 Financial Report According to the current regulations, Sword Group announces that its 2023 Financial Report has been made available to the public. It was sent to the Commission de Surveillance du Secteur Financier (CSSF) and was also filed with the Luxembourg Stock Exchange. It can be viewed and downloaded on the website of the company:Regulated Information Dividend €1.7 gross per shre Pending approval at the Annual General Meeting on April 29. Ex-date: April 30, 2024 - Payment: May 3, 2024 Calendar 25/04/24 | 2024 First Quarter Revenue 18/07/24 | 2024 Second Quarter Revenue About Sword Group Sword has 3,000+ IT/Digital specialists present over 5 continents to accompany you in the growth of your organisation in the digital age. As a leader in technological and digital transformation, Sword has a solid reputation in software publishing and in complex IT & business project management. Sword optimises your processes and enhances your data. Contact At

Sword Group: Information on the Number of Shares and Voting Rights at 29/02/202428.3.2024 18:00:00 CET | Press release

INFORMATION ON THE NUMBER OF SHARES AND VOTING RIGHTS AT 29/02/2024 Total Number of Shares: 9,544,965 Number of theoretical voting rights: 9,544,965 Number of exercisable voting rights: 9,398,264 Dividend €1.7 gross per shre Pending approval at the Annual General Meeting on April 29. Ex-date: April 30, 2024 - Payment: May 3, 2024 Calendar 25/04/24 | 2024 First Quarter Revenue 18/07/24 | 2024 Second Quarter Revenue About Sword Group Sword has 3,000+ IT/Digital specialists present over 5 continents to accompany you in the growth of your organisation in the digital age. As a leader in technological and digital transformation, Sword has a solid reputation in software publishing and in complex IT & business project management. Sword optimises your processes and enhances your data. Contact Attachment Sword Group SE Number of Shares & voting Rights published on 28032024

Sword Group: Availability of preparatory documents for the Ordinary General Meeting of 29 April 202428.3.2024 18:00:00 CET | Press release

The Ordinary General Meeting of Shareholders of Sword Group SE will be held at 11 a.m. on 29 April 2024. The notice of meeting including the agenda was published in the RESA (Recueil électronique des sociétés et associations) and in the Luxemburger Wort on 28 March 2024. The terms and conditions for attending and voting at this meeting are set out in this notice. The documents and information that must be provided at the General Meeting, together with the single form for participation, postal voting and proxy (the "Single Form"), are available on the Company's website here and at the registered office for an uninterrupted period commencing on the day of publication of this notice and ending on the day after the General Meeting. Upon presentation of their shares, shareholders may obtain copies of the documents free of charge under the applicable legal conditions. Registered shareholders must send the Company the duly completed, dated and signed Single Form, together, where applicable, w

HiddenA line styled icon from Orion Icon Library.Eye